Évaluation de l'efficacité et de l'innocuité du PT027 par rapport au PT007 administré selon les besoins chez les participants âgés de 12 à < 18 ans souffrant d'asthme (ACADIA)
Une étude randomisée, en double aveugle, multicentrique, en groupes parallèles, de phase IIIb de 52 semaines évaluant l'efficacité et l'innocuité du PT027 par rapport au PT007 administré selon les besoins chez des participants âgés de 12 à < 18 ans souffrant d'asthme (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: AstraZeneca Clinical Study Information Center
- Numéro de téléphone: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Lieux d'étude
-
-
-
Durban, Afrique du Sud, 4001
- Recrutement
- Research Site
-
Durban, Afrique du Sud, 3630
- Recrutement
- Research Site
-
Durban, Afrique du Sud, 4092
- Recrutement
- Research Site
-
Krugersdorp, Afrique du Sud, 1739
- Recrutement
- Research Site
-
Middelburg, Afrique du Sud, 1055
- Recrutement
- Research Site
-
Panorama, Afrique du Sud, 7500
- Recrutement
- Research Site
-
Somerset West, Afrique du Sud, 7130
- Pas encore de recrutement
- Research Site
-
Welkom, Afrique du Sud, 9460
- Recrutement
- Research Site
-
-
-
-
-
Beijing, Chine, 100191
- Recrutement
- Research Site
-
Beijing, Chine, 100050
- Recrutement
- Research Site
-
Bengbu, Chine, 233004
- Recrutement
- Research Site
-
Chengdu, Chine, 610066
- Recrutement
- Research Site
-
Chongqing, Chine, 401122
- Recrutement
- Research Site
-
Hohhot, Chine, 10050
- Recrutement
- Research Site
-
Mianyang, Chine, 621000
- Recrutement
- Research Site
-
Shanghai, Chine, 200433
- Recrutement
- Research Site
-
Shanghai, Chine
- Recrutement
- Research Site
-
Shanghai, Chine, 200062
- Recrutement
- Research Site
-
Shantou, Chine, 515041
- Recrutement
- Research Site
-
Shenyang, Chine, 110004
- Recrutement
- Research Site
-
Shenzhen, Chine, 518026
- Recrutement
- Research Site
-
Suzhou, Chine, 215002
- Recrutement
- Research Site
-
Taizhou, Chine, 318000
- Recrutement
- Research Site
-
Tianjin, Chine, 300211
- Recrutement
- Research Site
-
Tianjin, Chine, 300134
- Recrutement
- Research Site
-
Tianjin, Chine, 300050
- Recrutement
- Research Site
-
Wuhan, Chine, 430000
- Recrutement
- Research Site
-
Yanji, Chine, 133000
- Recrutement
- Research Site
-
Yantai, Chine, 264000
- Recrutement
- Research Site
-
Zhongshan, Chine, 528400
- Recrutement
- Research Site
-
-
-
-
-
Chihuahua City, Mexique, 31000
- Recrutement
- Research Site
-
Chihuahua City, Mexique, 31238
- Recrutement
- Research Site
-
Guadalajara, Mexique, 44100
- Recrutement
- Research Site
-
Guadalajara, Mexique, 44500
- Recrutement
- Research Site
-
Monterrey, Mexique, 64465
- Recrutement
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, États-Unis, 99508
- Recrutement
- Research Site
-
-
Arizona
-
Gilbert, Arizona, États-Unis, 85234
- Recrutement
- Research Site
-
Phoenix, Arizona, États-Unis, 85016
- Recrutement
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72202
- Complété
- Research Site
-
-
California
-
Huntington Beach, California, États-Unis, 92647
- Pas encore de recrutement
- Research Site
-
Huntington Beach, California, États-Unis, 92648
- Pas encore de recrutement
- Research Site
-
Long Beach, California, États-Unis, 90806
- Recrutement
- Research Site
-
Long Beach, California, États-Unis, 90815
- Recrutement
- Research Site
-
Madera, California, États-Unis, 93636
- Pas encore de recrutement
- Research Site
-
Mission Viejo, California, États-Unis, 92691
- Recrutement
- Research Site
-
Moreno Valley, California, États-Unis, 92553
- Recrutement
- Research Site
-
Orange, California, États-Unis, 92868
- Recrutement
- Research Site
-
Redondo Beach, California, États-Unis, 90277
- Recrutement
- Research Site
-
Riverside, California, États-Unis, 92506
- Recrutement
- Research Site
-
San Diego, California, États-Unis, 92123
- Pas encore de recrutement
- Research Site
-
San Diego, California, États-Unis, 92123
- Recrutement
- Research Site
-
San Francisco, California, États-Unis, 94143
- Retiré
- Research Site
-
Westminster, California, États-Unis, 92683
- Recrutement
- Research Site
-
-
Colorado
-
Denver, Colorado, États-Unis, 80206
- Recrutement
- Research Site
-
-
Delaware
-
Wilmington, Delaware, États-Unis, 19803
- Recrutement
- Research Site
-
-
Florida
-
Destin, Florida, États-Unis, 32541
- Recrutement
- Research Site
-
Jacksonville, Florida, États-Unis, 32207
- Recrutement
- Research Site
-
Kendall, Florida, États-Unis, 33176
- Pas encore de recrutement
- Research Site
-
Largo, Florida, États-Unis, 33777
- Complété
- Research Site
-
Miami, Florida, États-Unis, 33144
- Recrutement
- Research Site
-
Miami, Florida, États-Unis, 33145
- Recrutement
- Research Site
-
Miami, Florida, États-Unis, 33185
- Recrutement
- Research Site
-
Miami, Florida, États-Unis, 33142
- Recrutement
- Research Site
-
Miami, Florida, États-Unis, 33183
- Recrutement
- Research Site
-
Orlando, Florida, États-Unis, 32827
- Pas encore de recrutement
- Research Site
-
Pembroke Pines, Florida, États-Unis, 33026
- Recrutement
- Research Site
-
Tampa, Florida, États-Unis, 33613
- Retiré
- Research Site
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Recrutement
- Research Site
-
Columbus, Georgia, États-Unis, 31904
- Recrutement
- Research Site
-
Fayetteville, Georgia, États-Unis, 30214
- Recrutement
- Research Site
-
Snellville, Georgia, États-Unis, 30078
- Recrutement
- Research Site
-
-
Idaho
-
Meridian, Idaho, États-Unis, 83646
- Retiré
- Research Site
-
-
Illinois
-
Normal, Illinois, États-Unis, 61761
- Recrutement
- Research Site
-
River Forest, Illinois, États-Unis, 60305
- Retiré
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Research Site
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Recrutement
- Research Site
-
Overland Park, Kansas, États-Unis, 66213
- Pas encore de recrutement
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40217
- Recrutement
- Research Site
-
Louisville, Kentucky, États-Unis, 40202
- Recrutement
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, États-Unis, 70508
- Recrutement
- Research Site
-
New Orleans, Louisiana, États-Unis, 70121
- Recrutement
- Research Site
-
New Orleans, Louisiana, États-Unis, 70125
- Recrutement
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, États-Unis, 21043
- Recrutement
- Research Site
-
Lanham, Maryland, États-Unis, 20706
- Pas encore de recrutement
- Research Site
-
Silver Spring, Maryland, États-Unis, 20902
- Recrutement
- Research Site
-
White Marsh, Maryland, États-Unis, 21162
- Recrutement
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Pas encore de recrutement
- Research Site
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Recrutement
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, États-Unis, 56001
- Actif, ne recrute pas
- Research Site
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64118
- Recrutement
- Research Site
-
Kansas City, Missouri, États-Unis, 64108
- Retiré
- Research Site
-
St Louis, Missouri, États-Unis, 63108
- Recrutement
- Research Site
-
-
Montana
-
Missoula, Montana, États-Unis, 59804
- Recrutement
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68510
- Recrutement
- Research Site
-
Lincoln, Nebraska, États-Unis, 68516
- Recrutement
- Research Site
-
Omaha, Nebraska, États-Unis, 68114
- Recrutement
- Research Site
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07103
- Recrutement
- Research Site
-
Newark, New Jersey, États-Unis, 07103
- Pas encore de recrutement
- Research Site
-
Northfield, New Jersey, États-Unis, 08225
- Recrutement
- Research Site
-
Ocean City, New Jersey, États-Unis, 07712
- Recrutement
- Research Site
-
Paramus, New Jersey, États-Unis, 07652
- Recrutement
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- Recrutement
- Research Site
-
-
New York
-
Albany, New York, États-Unis, 12208
- Recrutement
- Research Site
-
Cortland, New York, États-Unis, 13045
- Recrutement
- Research Site
-
Hawthorne, New York, États-Unis, 10532
- Recrutement
- Research Site
-
Hollis, New York, États-Unis, 11423
- Retiré
- Research Site
-
New York, New York, États-Unis, 10032
- Recrutement
- Research Site
-
New York, New York, États-Unis, 11355
- Recrutement
- Research Site
-
New York, New York, États-Unis, 10019
- Retiré
- Research Site
-
Rochester, New York, États-Unis, 14607
- Complété
- Research Site
-
The Bronx, New York, États-Unis, 10459
- Recrutement
- Research Site
-
The Bronx, New York, États-Unis, 10461
- Recrutement
- Research Site
-
Vestal, New York, États-Unis, 13850
- Recrutement
- Research Site
-
Vestal, New York, États-Unis, 13850
- Retiré
- Research Site
-
Watertown, New York, États-Unis, 13601
- Recrutement
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28277
- Retiré
- Research Site
-
Durham, North Carolina, États-Unis, 27705
- Pas encore de recrutement
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Pas encore de recrutement
- Research Site
-
Columbus, Ohio, États-Unis, 43205
- Pas encore de recrutement
- Research Site
-
Columbus, Ohio, États-Unis, 43228
- Recrutement
- Research Site
-
Dayton, Ohio, États-Unis, 45424
- Recrutement
- Research Site
-
Findlay, Ohio, États-Unis, 45840
- Recrutement
- Research Site
-
Toledo, Ohio, États-Unis, 43617
- Recrutement
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73120
- Recrutement
- Research Site
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- Research Site
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Pas encore de recrutement
- Research Site
-
Yukon, Oklahoma, États-Unis, 73099
- Recrutement
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15241
- Recrutement
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Recrutement
- Research Site
-
Rock Hill, South Carolina, États-Unis, 29730
- Complété
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57105
- Recrutement
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Research Site
-
-
Texas
-
Austin, Texas, États-Unis, 78759
- Recrutement
- Research Site
-
Baytown, Texas, États-Unis, 77521
- Recrutement
- Research Site
-
Beaumont, Texas, États-Unis, 77701
- Recrutement
- Research Site
-
Beaumont, Texas, États-Unis, 77702
- Recrutement
- Research Site
-
Bellaire, Texas, États-Unis, 77401
- Recrutement
- Research Site
-
Corpus Christi, Texas, États-Unis, 78411
- Recrutement
- Research Site
-
Corsicana, Texas, États-Unis, 75110
- Recrutement
- Research Site
-
Dallas, Texas, États-Unis, 75231
- Recrutement
- Research Site
-
Dallas, Texas, États-Unis, 75235
- Recrutement
- Research Site
-
El Paso, Texas, États-Unis, 79912
- Recrutement
- Research Site
-
Frisco, Texas, États-Unis, 75034
- Retiré
- Research Site
-
Houston, Texas, États-Unis, 77099
- Recrutement
- Research Site
-
Houston, Texas, États-Unis, 77030
- Pas encore de recrutement
- Research Site
-
Houston, Texas, États-Unis, 77065
- Recrutement
- Research Site
-
Kerrville, Texas, États-Unis, 78028
- Retiré
- Research Site
-
McKinney, Texas, États-Unis, 75069
- Recrutement
- Research Site
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Research Site
-
San Antonio, Texas, États-Unis, 78215
- Recrutement
- Research Site
-
San Antonio, Texas, États-Unis, 78249
- Pas encore de recrutement
- Research Site
-
Tyler, Texas, États-Unis, 75708
- Complété
- Research Site
-
-
Utah
-
West Jordan, Utah, États-Unis, 84088
- Recrutement
- Research Site
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05405
- Recrutement
- Research Site
-
-
Virginia
-
Burke, Virginia, États-Unis, 22015
- Retiré
- Research Site
-
-
Washington
-
Bellingham, Washington, États-Unis, 98225
- Complété
- Research Site
-
Vancouver, Washington, États-Unis, 98664
- Recrutement
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Autres noms:
|
|
Comparateur actif: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
Délai: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
Délai: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
Délai: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
Délai: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Délai: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- D6934C00001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .